Overview

Corneal Versus Conjunctival Delivery Using a Delivery Device

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Compare the antihypertensive efficacy of three methods for installing Xalatan
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Latanoprost